PDCD1 and neoplasm: These results indicate that while LIT has limited effect on the secondary B16 tumors, but LIT combined with a checkpoint inhibitor (anti-PD-1) could have synergistic effects on both tumor cells and CTLs, potentially achieving an optimized anti-tumor effect on secondary tumors.